Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

Community driven content discussing all aspects of software development from DevOps to design patterns. Ready to develop your first AWS Lambda function in Python? It really couldn’t be easier. The AWS ...

Thinking about learning Python? It’s a pretty popular language these days, and for good reason. It’s not super complicated, which is nice if you’re just starting out. We’ve put together a guide that ...

If you’re new to Python, one of the first things you’ll encounter is variables and data types. Understanding how Python handles data is essential for writing clean, efficient, and bug-free programs.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 ...

In any Tkinter program, the first thing you need is a window. This window will act as a container for your app. This line brings the Tkinter library into your program. We give it the nickname tk so we ...

This tutorial will guide you through the process of using SQL databases with Python, focusing on MySQL as the database management system. You will learn how to set up your environment, connect to a ...

An experimental ‘no-GIL’ build mode in Python 3.13 disables the Global Interpreter Lock to enable true parallel execution in Python. Here’s where to start. The single biggest new feature in Python ...

On Aug. 8, Recursion Pharmaceuticals announced its intention to merge with Exscientia in an all-stock deal. Recursion Pharmaceuticals and Exscientia are both pharma-tech companies that aim to improve ...